Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Polyethylene Glycol Market by Grade, Form (Liquid, White wax, Flake/Powder), Package Size (Drums, Bulk Container, Glass Bottles), End-Use Industry (Pharmaceutical, Cosmetics & Personal care, Food & Beverage, Industrial) & Region - Global Forecast to 2029
... widely used for drug formulations and delivery systems in pharmaceutical industries. It enhances the solubility and bioavailability of poorly soluble drugs. Additionally, due to its low toxicity and non-irritating properties it is widely used in ... Read More
-
Pharmaceutical Grade Silica Gel
... 2030, growing at a CAGR of 8.6% over the analysis period 2024-2030. Desiccant Application, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$81.0 Million by the ... Read More
-
Proanthocyanidins
... 6.2% over the analysis period 2024-2030. Cranberry Source, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$177.2 Million by the end of the analysis period. Growth ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Pharmaceutical Membrane Filtration
... at a CAGR of 10.5% over the analysis period 2024-2030. Membrane Filters, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$11.7 Billion by the end of ... Read More
-
Sustained Release Excipients
... at a CAGR of 6.0% over the analysis period 2024-2030. Polymers, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.2 Billion by the end of the ... Read More
-
Myeloproliferative Disorders Drugs
... at a CAGR of 4.3% over the analysis period 2024-2030. Ph+ Chronic Myelogenous Leukemia (CML) Drugs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$9.2 Billion ... Read More
-
Attapulgite
... 6.9% over the analysis period 2024-2030. Colloidal grade Attapulgite, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$320.0 Million by the end of the analysis period. ... Read More
-
Pharmaceutical Chemicals
... CAGR of 4.9% over the analysis period 2024-2030. OTC Drugs, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$16.8 Billion by the end of the analysis ... Read More
-
Biotechnology / Pharmaceutical Services Outsourcing
... Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Consulting Services, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$20.9 Billion ... Read More
-
Diabetes Drugs
... CAGR of 9.3% over the analysis period 2024-2030. Oral Drugs, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$163.4 Billion by the end of the analysis ... Read More
-
Atopic Dermatitis Drugs
... at a CAGR of 21.1% over the analysis period 2024-2030. Biologics Drug Class, one of the segments analyzed in the report, is expected to record a 22.7% CAGR and reach US$18.7 Billion by the end ... Read More
-
Alopecia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Topical Drugs, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$8.4 Billion by the end of the analysis ... Read More
-
Microencapsulation
... 12.4% over the analysis period 2024-2030. Spray Technology, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$10.2 Billion by the end of the analysis period. Growth ... Read More
-
Sterility Testing
... CAGR of 10.9% over the analysis period 2024-2030. Sterility Testing Kits & Reagents, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$184.9 Million by the end ... Read More
-
Superdisintegrants
... 5.4% over the analysis period 2024-2030. Synthetic Superdisintegrants, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$262.2 Million by the end of the analysis period. Growth ... Read More
-
Triacetin
... 4.3% over the analysis period 2024-2030. Triacetin Plasticizer, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$193.2 Million by the end of the analysis period. Growth ... Read More
-
Orphan Drugs
... CAGR of 12.0% over the analysis period 2024-2030. Biologic Drugs, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$308.5 Billion by the end of the analysis ... Read More
-
Ginseng
... 10.2% over the analysis period 2024-2030. Asian Ginseng, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$11.2 Billion by the end of the analysis period. Growth ... Read More
-
Pharmaceutical Processing Seals
... at a CAGR of 8.2% over the analysis period 2024-2030. O-Rings, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$2.8 Billion by the end of the ... Read More
-
Myelodysplastic Syndrome (MDS) Drugs
... 2030, growing at a CAGR of 9.3% over the analysis period 2024-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$2.7 Billion by the ... Read More
-
Pharmaceutical Robots
... CAGR of 7.6% over the analysis period 2024-2030. Traditional Robots, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$224.1 Million by the end of the analysis ... Read More
-
Pharmaceutical Filtration
... CAGR of 17.2% over the analysis period 2024-2030. Membrane Filters, one of the segments analyzed in the report, is expected to record a 21.2% CAGR and reach US$19.6 Billion by the end of the analysis ... Read More
-
Healthcare Contract Development and Manufacturing Organization
... reach US$547.1 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Contract Manufacturing, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach ... Read More
-
Contract Packaging
... CAGR of 8.7% over the analysis period 2024-2030. Food & Beverage End-Use, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$55.4 Billion by the end of ... Read More
Research Assistance
